Cargando…

Oral miltefosine for refractory Acanthamoeba keratitis

PURPOSE: To report the first case of Acanthamoeba keratitis treated with oral miltefosine in the United States. OBSERVATIONS: A 17-year-old female with a history of orthokeratology contact lens wear presented after five months of left eye pain, redness, and photophobia. She was previously treated wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirabayashi, Kristin E., Lin, Charles C., Ta, Christopher N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804782/
https://www.ncbi.nlm.nih.gov/pubmed/31650083
http://dx.doi.org/10.1016/j.ajoc.2019.100555
_version_ 1783461266989252608
author Hirabayashi, Kristin E.
Lin, Charles C.
Ta, Christopher N.
author_facet Hirabayashi, Kristin E.
Lin, Charles C.
Ta, Christopher N.
author_sort Hirabayashi, Kristin E.
collection PubMed
description PURPOSE: To report the first case of Acanthamoeba keratitis treated with oral miltefosine in the United States. OBSERVATIONS: A 17-year-old female with a history of orthokeratology contact lens wear presented after five months of left eye pain, redness, and photophobia. She was previously treated with antivirals and topical corticosteroids for presumed herpetic disease. She was found to have a large central ring infiltrate and corneal cultures were positive for Acanthamoeba. The infection progressed despite hourly PHMB 0.02% and chlorhexidine 0.02%, and oral vorizonazole. The patient was started on oral miltefosine 50 mg 3 times per day. Following one week of treatment, repeat cultures were positive for Acanthamoeba and therefore, the concentration of chlorhexidine was increased from 0.02% to 0.06% and PHMB was changed to propamidine isetionate (Brolene 0.1%). There was definite clinical improvement after five weeks of treatment with oral miltefosine, topical chlorhexidine 0.06% and propamidine isetionate 0.1%. CONCLUSIONS AND IMPORTANCE: Acanthamoeba keratitis is a challenging entity to treat and often associated with a poor prognosis. Oral miltefosine may offer additional therapeutic benefit in cases of refractory Acanthamoeba keratitis.
format Online
Article
Text
id pubmed-6804782
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-68047822019-10-24 Oral miltefosine for refractory Acanthamoeba keratitis Hirabayashi, Kristin E. Lin, Charles C. Ta, Christopher N. Am J Ophthalmol Case Rep Case Report PURPOSE: To report the first case of Acanthamoeba keratitis treated with oral miltefosine in the United States. OBSERVATIONS: A 17-year-old female with a history of orthokeratology contact lens wear presented after five months of left eye pain, redness, and photophobia. She was previously treated with antivirals and topical corticosteroids for presumed herpetic disease. She was found to have a large central ring infiltrate and corneal cultures were positive for Acanthamoeba. The infection progressed despite hourly PHMB 0.02% and chlorhexidine 0.02%, and oral vorizonazole. The patient was started on oral miltefosine 50 mg 3 times per day. Following one week of treatment, repeat cultures were positive for Acanthamoeba and therefore, the concentration of chlorhexidine was increased from 0.02% to 0.06% and PHMB was changed to propamidine isetionate (Brolene 0.1%). There was definite clinical improvement after five weeks of treatment with oral miltefosine, topical chlorhexidine 0.06% and propamidine isetionate 0.1%. CONCLUSIONS AND IMPORTANCE: Acanthamoeba keratitis is a challenging entity to treat and often associated with a poor prognosis. Oral miltefosine may offer additional therapeutic benefit in cases of refractory Acanthamoeba keratitis. Elsevier 2019-09-19 /pmc/articles/PMC6804782/ /pubmed/31650083 http://dx.doi.org/10.1016/j.ajoc.2019.100555 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Hirabayashi, Kristin E.
Lin, Charles C.
Ta, Christopher N.
Oral miltefosine for refractory Acanthamoeba keratitis
title Oral miltefosine for refractory Acanthamoeba keratitis
title_full Oral miltefosine for refractory Acanthamoeba keratitis
title_fullStr Oral miltefosine for refractory Acanthamoeba keratitis
title_full_unstemmed Oral miltefosine for refractory Acanthamoeba keratitis
title_short Oral miltefosine for refractory Acanthamoeba keratitis
title_sort oral miltefosine for refractory acanthamoeba keratitis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804782/
https://www.ncbi.nlm.nih.gov/pubmed/31650083
http://dx.doi.org/10.1016/j.ajoc.2019.100555
work_keys_str_mv AT hirabayashikristine oralmiltefosineforrefractoryacanthamoebakeratitis
AT lincharlesc oralmiltefosineforrefractoryacanthamoebakeratitis
AT tachristophern oralmiltefosineforrefractoryacanthamoebakeratitis